Johann Colomba

Johann Colomba

Auto-generated profile, based on publicly available information

Johann Colomba

Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Paris, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
JCJohann Colomba
Johann Colomba
VBValérie Boudreau
Valérie Boudreau
CLCatherine Lehoux-Dubois
Catherine Lehoux-Dubois
KDKatherine Desjardins
Katherine Desjardins
ACAdèle Coriati
Adèle Coriati
RRRémi Rabasa-Lhoret
Rémi Rabasa-Lhoret

11 March 2021 in Diabetologia
Verified
Journal Article
Closed access
PDF file
ABAnne Bonhoure
Anne Bonhoure
KPKathryn J. Potter
Kathryn J. Potter
JCJohann Colomba
Johann Colomba
VBValérie Boudreau
Valérie Boudreau
CBCindy Bergeron
Cindy Bergeron
RRRémi Rabasa-Lhoret
Rémi Rabasa-Lhoret

18 July 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJohann Colomba
Johann Colomba
SNSilvia R. Netedu
Silvia R. Netedu
CLCatherine Lehoux-Dubois
Catherine Lehoux-Dubois
ACAdèle Coriati
Adèle Coriati
VBValérie Boudreau
Valérie Boudreau
JLJulio A. Leey
Julio A. Leey
Cystic fibrosis (CF) patients are at high risk of developing CF-related diabetes (CFRD). In non-CF patients, liver disease, specifically steatosis and non-alcoholic fatty liver disease (NAFLD), is strongly associated with type 2 diabetes. We compared glycemic status and metabolic profiles in CF patients according to a biomarker of hepatic injury, alanine aminotransferase (ALT). We conducted a cross-sectional study among 273 adult CF patients recruited from the Montreal CF Cohort. A 2-hour oral glucose tolerance test (OGTT) was performed to collect glucose and insulin measures every 30 minutes. Fasting ALT levels and anthropometric measures were also obtained. Patients were categorized into 2 groups based on ALT cut-off of 25 U/L. Patients in the high ALT group were mostly men (83%), had higher mean weight and BMI (p<0.001) and showed elevated glucose levels throughout OGTT (p≤0.01). When stratified by sex, only men with high ALT showed significantly higher weight (p<0.001), higher glycemic values at 60, 90 and 120 minutes of OGTT (p≤0.01), higher frequency of de novo CFRD (20.5% vs 8.2%, p = 0.04) as well as lower insulin sensitivity than men with normal ALT (p = 0.03). ALT levels were strongly associated with HOMA-IR in CFRD patients (p = 0.001, r2 = 0.28). Adult CF men with higher ALT show an increased frequency of dysglycemia and de novo CFRD, lower insulin sensitivity and higher eight. Our data suggests that ALT levels could be an interesting tool to guide targeted diabetes screening, particularly among CF men. Prospective studies are needed to confirm these observations.

1 September 2020 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
JCJohann Colomba
Johann Colomba
RRRémi Rabasa-Lhoret
Rémi Rabasa-Lhoret
ABAnne Bonhoure
Anne Bonhoure
CBCindy Bergeron
Cindy Bergeron
VBValérie Boudreau
Valérie Boudreau
KPKathryn Potter
Kathryn Potter

21 September 2021 in Annals of Oncology
Verified
Journal Article
Closed access
MPM. Patel
M. Patel
EFEudald Felip
Eudald Felip
RSR. Sharkey
R. Sharkey
MKMarco Krengli
Marco Krengli
JCJ.D. Chester
J.D. Chester
ACAlessio Cortellini
Alessio Cortellini